Method for Predicting Clinical benefit in the treatment of Neurodevelopmental Disorders, neurological or Neuropsychiatric

摘要

This refers to an in vitro method to predict Response of patients with Neurodevelopmental Disorders, neurological or Neuropsychiatric, if they were treated with a compound with Diana at the glutamatergic Pathway, which includes the following steps: i. ) to determine the Protein concentration of one, two, three, Four,Five or six members of the family of Complement Factor H or a mixture or combination thereof in a sample from a patient, (ii) to compare the Protein concentration determined in phase I) with a representative value of the Protein Content of one, two, three, Four,Five or six members of the family of Complement Factor H in patients with Neurodevelopmental Disorders, neurological or Neuropsychiatric, III) in which a higher Protein concentration of one, two, three, Four, five or six members of the family of the facto R H complement in the patient Sample with Neurodevelopmental DisordersNeurological or Neuropsychiatric is indicative of a patient obtained a Clinical benefit from the treatment, and (iv) to select treatment for Patients with Neurodevelopmental Disorders, neurological or Neuropsychiatric.Claim 12: using an Antibody specifically Binding to a Protein of the family of Complement Factor H in a method according to claims 1 to 9. Claim 15: members of the family of Complement Factor H for the use as a Predictive marker for patients who have been treated with compounds with Diana at the glutamatergic Pathway.